BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 2241435)

  • 1. Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use.
    Sugar AM
    Arch Intern Med; 1990 Nov; 150(11):2258-64. PubMed ID: 2241435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques.
    Sobel JD
    Pharmacotherapy; 2006 Jun; 26(6 Pt 2):47S-54S. PubMed ID: 16716122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empiric antifungal therapy in patients with febrile neutropenia.
    Ferrara JJ; MacDougall C; Gallagher JC
    Pharmacotherapy; 2011 Apr; 31(4):369-85. PubMed ID: 21449626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
    Rex JH; Walsh TJ; Sobel JD; Filler SG; Pappas PG; Dismukes WE; Edwards JE
    Clin Infect Dis; 2000 Apr; 30(4):662-78. PubMed ID: 10770728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antimicrobial prophylaxis and therapy in neutropenia].
    Link H
    Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D; Buadi FK; McClune B
    Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical antifungal therapy in febrile neutropenic patients: current status.
    Kibbler CC
    Curr Top Med Mycol; 1997 Dec; 8(1-2):5-14. PubMed ID: 9504062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.
    Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Suguro M; Arai C; Matsuyama T; Takezako N; Miwa A; Kern W; Kami M; Akiyama H; Hirai H; Togawa A
    Cancer; 2000 Oct; 89(7):1611-25. PubMed ID: 11013378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
    Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
    Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empirical antifungal therapy in treating febrile neutropenic patients.
    Wingard JR
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S38-43. PubMed ID: 15250019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients.
    Bennett JE; Powers J; Walsh T; Viscoli C; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Kauffman C; Lee J; Pappas P; Rex J; Verweij P
    Clin Infect Dis; 2003 Apr; 36(Suppl 3):S117-22. PubMed ID: 12679895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
    Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Empirical antibiotic therapy in febrile neutropenic patients with acute leukemia].
    Yabe H; Nakamura F; Ishikawa T; Nagai K; Nakayama S
    Rinsho Ketsueki; 1989 May; 30(5):644-9. PubMed ID: 2795878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine.
    Silling G; Fegeler W; Roos N; Essink M; Büchner T
    Mycoses; 1999; 42 Suppl 2():101-4. PubMed ID: 10865914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of mycoses in surgical patients -- review of the literature.
    Holzheimer RG; Dralle H
    Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.